Association of High Blood Homocysteine and Risk of Increased Severity of Ischemic Stroke Events

Abstract

Stroke is the leading cause of death and disability in the world as well as in Indonesia. Initial stroke severity is an important factor that affects short- and long-term stroke outcomes. This cross-sectional study was conducted in Cipto Mangunkusumo Hospital from July 2017 to January 2018 to investigate the factors that affect stroke severity. A total of 77 acute ischemic stroke patients were divided into three groups, which include low blood homocysteine levels (< 9 μmol/L), moderate blood homocysteine levels (9–15 μmol/L), and high blood homocysteine levels (> 15 μmol/L). The acquired data were analyzed using Kruskal–Wallis test and a significant difference of initial National Institute of Health Stroke Scale (NIHSS) and blood homocysteine levels (H = 13.328, p = 0.001) were seen, with a mean rank of 25.86 for low blood homocysteine levels, 33.69 for moderate blood homocysteine levels, and 48.94 for high blood homocysteine levels. The patients were then divided into two groups based on the NIHSS (≤5 and > 5) to calculate the risk correlation of blood homocysteine levels and NIHSS by using regression. We found that patients with high blood homocysteine levels had 14.4 times higher risk of having NIHSS > 5 compared with those with low blood homocysteine levels (p = 0.002, 95% confidence interval [CI] [2.714–76.407]), and 3.9 times higher risk compared with those with moderate blood homocysteine levels (p = 0.011, 95% CI [1.371–11.246]). We concluded that homocysteine is a risk factor for a higher stroke severity. Future studies to evaluate the usefulness of homocysteine-lowering therapy in stroke patients are recommended.

Keywords

acute ischemic stroke - homocysteine - NIHSS - stroke severity

Note

This study has been approved by Ethics Committee of Faculty of Medicine, Indonesia University.

• References

• 1 Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol 2007; 6 (02) 182-187
• 2 Mihardja LK. . Delima, Soetiarto F. , Suhardi, Kristanto AY. Penyakit tidak menular. In: Riset Kesehatan Dasar. Jakarta: Indonesian Ministry of Health; 2013
• 3 Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res 2017; 120 (03) 439-448
• 4 Rost NS, Bottle A, Lee JM. , et al; Global Comparators Stroke GOAL collaborators. Stroke severity is a crucial predictor of outcome: an international prospective validation study. J Am Heart Assoc 2016; 5 (01) e002433
• 5 Weimar C, König IR, Kraywinkel K, Ziegler A, Diener HC. ; German Stroke Study Collaboration. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke 2004; 35 (01) 158-162
• 6 Jørgensen H, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke 1994; 25 (10) 1977-1984
• 7 Liu CH, Wei YC, Lin JR. , et al; Stroke Registry in Chang Gung Healthcare System (SRICHS) Investigators. Initial blood pressure is associated with stroke severity and is predictive of admission cost and one-year outcome in different stroke subtypes: a SRICHS registry study. BMC Neurol 2016; 16: 27
• 8 Vemmos KN, Tsivgoulis G, Spengos K. , et al. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med 2004; 255 (02) 257-265
• 9 McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56 (01) 111-128
• 10 Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. ; Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009; 40 (04) 1365-1372
• 11 Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr 2006; 136 (6, Suppl): 1741S-1749S
• 12 Vayá A, Ejarque I, Tembl J, Corella D, Laiz B. Hyperhomocysteinemia, obesity and cryptogenic stroke. Clin Hemorheol Microcirc 2011; 47 (01) 53-58
• 13 Waśkiewicz A, Sygnowska E, Broda G. Homocysteine concentration and the risk of death in the adult Polish population. Kardiol Pol 2012; 70 (09) 897-902
• 14 Vollset SE, Refsum H, Tverdal A. , et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 2001; 74 (01) 130-136
• 15 He Y, Li Y, Chen Y, Feng L, Nie Z. Homocysteine level and risk of different stroke types: a metanalysis of prospective observational studies. Nutr Metab Cardiovasc Dis 2014; 24 (11) 1158-1165
• 16 Perini F, Galloni E, Bolgan I. , et al. Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: stronger association with small artery disease. Neurol Sci 2005; 26 (05) 310-318
• 17 Yao XY, Lin Y, Geng JL. , et al. Age- and gender-specific prevalence of risk factors in patients with first-ever ischemic stroke in china. Stroke Res Treat 2012; 2012: 136398
• 18 Zhang Y, Shi Z, Liang H. , et al. Prevalence of hypertension in Chinese population aged over 40 and subgroup of survival stroke patients. Biomed Res 2016; 27 (03) 917-922
• 19 Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006; 26 (06) 1397-1404
• 20 Sauls DL, Lockhart E, Warren ME, Lenkowski A, Wilhelm SE, Hoffman M. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry 2006; 45 (08) 2480-2487
• 21 Derrick L, Sauls DL, Lockhart E, Hoffman M. Reaction of fibrinogen with homocysteine thiolactone mimics the dysfibrinogenemia produced by hyperhomocysteinemia. Blood 2005; 106: 137
• 22 Ferguson E, Hogg N, Antholine WE. , et al. Characterization of the adduct formed from the reaction between homocysteine thiolactone and low-density lipoprotein: antioxidant implications. Free Radic Biol Med 1999; 26 (7-8): 968-977
• 23 Johansson BB. Hypertension mechanisms causing stroke. Clin Exp Pharmacol Physiol 1999; 26 (07) 563-565
• 24 Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PAG. ; IST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33 (05) 1315-1320
• 25 Tuttolomondo A, Maida C, Maugeri R, Iacopino G, Pinto A. Relationship between diabetes and ischemic stroke: analysis of diabetes-related risk factors for stroke and of specific patterns of stroke associated with diabetes mellitus. J Diabetes Metab 2015; 6: 5
• 26 Gerstein HC, Miller ME, Byington RP. , et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358 (24) 2545-2559
• 27 Patibandla S, Appikatla T, Jayasingh K. Study of the severity of stroke at the time of presentation in diabetic patients correlating with glycemic control. Int J Adv Med 2017; 4 (02) 396-400